hVIVO (LON:HVO) Trading Down 46.3% - Here's What Happened

hVIVO plc (LON:HVO - Get Free Report) dropped 46.3% during trading on Friday . The company traded as low as GBX 6.50 ($0.09) and last traded at GBX 8.70 ($0.12). Approximately 83,062,000 shares traded hands during mid-day trading, an increase of 2,325% from the average daily volume of 3,424,608 shares. The stock had previously closed at GBX 16.20 ($0.22).

Wall Street Analyst Weigh In

Separately, Shore Capital reiterated a "buy" rating on shares of hVIVO in a research report on Friday.

hVIVO Trading Down 46.3%

The stock has a 50-day moving average of GBX 16.16 and a 200 day moving average of GBX 18.13. The stock has a market cap of £61.56 million, a PE ratio of 3.59 and a beta of 0.97. The company has a quick ratio of 1.16, a current ratio of 1.61 and a debt-to-equity ratio of 33.86.

hVIVO (LON:HVO - Get Free Report) last announced its quarterly earnings results on Thursday, April 10th. The company reported GBX 1.69 ($0.02) earnings per share (EPS) for the quarter. hVIVO had a return on equity of 47.93% and a net margin of 25.96%. As a group, sell-side analysts anticipate that hVIVO plc will post 1.5492958 earnings per share for the current year.

Insider Buying and Selling at hVIVO

In other news, insider Yamin Mo' Khan sold 3,062,246 shares of hVIVO stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of GBX 17 ($0.23), for a total value of £520,581.82 ($700,648.48). 14.03% of the stock is currently owned by corporate insiders.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.